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Abstract
Objective:  Comparative  and  descriptive  analysis  of  the  outcomes  of  percutaneous  access  for
EVAR (pEVAR)  compared  to  the  control  group  submitted  to  surgical  femoral  access  (cEVAR).
Methods:  Retrospective  case--control  analysis  between  January  2013  and  January  2015  of  the
outcomes  of  pEVAR  (group  1)  compared  to  a  control  group  of  cEVAR  (group  2)  taking  into  account
the demographic  data  and  the  primary  endpoints:  Access  complication  and  surgical  time;  and
secondary  endpoints:  type  of  anaesthesia,  length  of  hospital  stay  and  hematic  loss.  The  statis-
tical analysis  was  performed  with  the  SPSS  23.0  programme  using  the  X2  test  for  categorical
variables  and  t  test  for  continuous  variables.
Results:  A  total  of  6  pEVAR  cases  were  performed  in  the  selected  period.  A  random  selection  of
20 cEVAR  control  cases  was  obtained.  The  mean  age  was  75  years,  85%  were  male.  There  were
no signiﬁcant  differences  in  comorbidities  between  the  two  groups;  the  most  frequent
were arterial  hypertension,  dyslipidaemia,  COPD/CID  and  CRD.  There  were  no  differences  in
major access  complications  (haemorrhage,  lymphatic  drainage,  pain  and  oedema),  however
more frequently  in  cEVAR,  with  a  signiﬁcant  rate  of  minor  complications  such  as  bruising  in  pEVAR
(3.5% vs.  11.5%,  p  =  0.008).  The  surgical  time  was  not  signiﬁcantly  higher  in  cEVAR  (p  =  0.21),
but the  median  is  greater  than  in  pEVAR  with  equally  high  in-group  variance  (cEVAR  vs.  pEVAR:
169 vs.  209  min;  ANOVA:  p  <  0.05).  Analysing  secondary  endpoints,  the  most  widely  used  anaes-
thesia was  the  epidural  (p  =  0.03),  hospital  stay  was  higher  in  cEVAR  (6.15  vs.  3.17;  p  =  0.022),
a fact  not  observed  in  hematic  loss  (p  =  0.17)  despite  the  trend  towards  greater  loss  in  cEVAR
(group 1  and  2:  1.4  vs.  2.8  mg/dl).
Conclusion:  Percutaneous  access  for  EVAR  demonstrates  equal  efﬁcacy  and  safety  compared
to surgical  femoral  access,  with  shorter  surgical  time  and  hospitalization  and  less  hematic  loss
without increasing  local  complications.
©  2016  Sociedade  Portuguesa  de  Angiologia  e  Cirurgia  Vascular.  Published  by  Elsevier  Espan˜a,
S.L.U. This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.
).org/licenses/by-nc-nd/4.0/∗ Corresponding author.
E-mail address: mariojmvieira@hotmail.com (M.M. Vieira).
ttp://dx.doi.org/10.1016/j.ancv.2016.08.003
646-706X/© 2016 Sociedade Portuguesa de Angiologia e Cirurgia Vascular. Published by Elsevier Espan˜a, S.L.U. This is an open access article
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Acesso  percutâneo  para  EVAR:  estudo  caso-controlo
Resumo
Objetivo:  Análise  comparativa  e  descritiva  dos  resultados  do  acesso  percutâneo  para  EVAR
(pEVAR) e  do  grupo  de  controlo  submetido  a  acesso  femoral  cirúrgico  (cEVAR).
Métodos: Análise  retrospetiva  caso-controlo  entre  janeiro  de  2013  e  janeiro  de  2015  dos  result-
ados do  pEVAR  (grupo  1)  em  comparac¸ão  com  grupo  de  controlo  de  cEVAR  (grupo  2),  tendo  como
endpoints primários  --  complicac¸ão  de  acesso  e  tempo  cirúrgico  --  e  os  endpoints  secundários
-- tipo  de  anestesia,  tempo  de  internamento  e  perda  hemática.  A  análise  foi  efetuada  utilizando
o programa  SPSS  23.0,  com  os  testes  X2  para  variáveis  categóricas  e  teste  t  para  variáveis
contínuas.
Resultados:  Foram  obtidos  6  casos  de  pEVAR  no  período  selecionado  e  realizada  uma  selec¸ão
aleatória de  20  casos-controlo  de  cEVAR.  A  idade  média  foi  de  75  anos,  sendo  85%  do  sexo  mas-
culino. Não  se  veriﬁcou  diferenc¸a  signiﬁcativa  nas  comorbilidades  entre  os  2  grupos,  sendo  as
mais frequentes  a  HTA,  a  dislipidemia,  a  DPCO/DCI  e  a  IRC.  Não  se  observou  diferenc¸a  signiﬁca-
tiva nas  complicac¸ões  major  de  acesso  (hemorragia,  linforragia,  dor  e  edema),  mais  frequentes,
contudo,  no  cEVAR,  sendo  signiﬁcativa  a  taxa  de  complicac¸ões  minor  como  equimoses  no  pEVAR
(11,5%, p  =  0,08).  O  tempo  cirúrgico  não  foi  signiﬁcativamente  superior  no  cEVAR  (p  =  0,21),
contudo a  mediana  é  superior  ao  pEVAR  (pEVAR  vs.  cEVAR:  169  vs.  209  minutos;  ANOVA  teste:
p <  0,05).  Quanto  aos  endpoints  secundários,  o  tipo  de  anestesia  mais  utilizado  foi  a  epidural
(p =  0,03);  o  tempo  de  internamento  em  dias  foi  superior  no  cEVAR  (6,15  vs.  3,17;  p  =  0,022),
facto não  observado  na  perda  hemática  (p  =  0,17),  apesar  da  tendência  para  maior  perda  no
cEVAR (grupo  1  e  2:  1,4  vs.  2,8  mg/dl).
Conclusão:  O  acesso  percutâneo  para  EVAR  demonstra  igual  eﬁcácia  e  seguranc¸a em  relac¸ão
ao acesso  femoral  cirúrgico,  com  menor  tempo  cirúrgico  e  internamento,  sem  aumento  das
complicac¸ões locais.
© 2016  Sociedade  Portuguesa  de  Angiologia  e  Cirurgia  Vascular.  Publicado  por  Elsevier  Espan˜a,
S.L.U. Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
t
i
t
M
R
d
2
t
f
g
a
f
a
(
s
t
f
i
or  ruptured  aneurysm;  (c)  complex  aortic,  iliac  or  femoralIntroduction
Since  ﬁrst  implant  by  Parodi  in  1990,  the  endovascular  repair
of  abdominal  aortic  aneurysms  (EVAR)  has  gained  accep-
tance  and  application  in  vascular  community.  Despite  recent
randomized  trials  did  not  demonstrate  beneﬁt  of  EVAR  in  the
ﬁrst  30  days  overall  mortality,  with  increase  of  reinterven-
tion  rate,1--3 the  total  number  of  procedures  has  increased
globally,  with  concomitant  increase  of  indications.
It  has  been  observed  in  recent  years  a  need  to  reduce
aggression  in  medical,  surgical  and  anaesthetic  procedures.
As  EVAR  was  traditionally  carried  out  by  direct  femoral
artery  catheterization  after  surgical  exposure,  there  was
a  recent  trend  for  introduction  of  percutaneous  arterial
access,  with  a  theoretical  reduction  of  surgical  and  anaes-
thetic  aggressiveness.
As  demonstrated  by  recent  data  as  PEVAR  Trial,4 the  per-
cutaneous  implantation  of  aortic  endografts  (pEVAR)  has
been  associated  with  decreased  operative  time  and  hospital
stay  without  increasing  local  complications,  being  a  safe  and
effective  technic.  It  is  also  associated  with  shorter  anaes-
thetic  time  and  aggression,  with  early  onset  of  normal  daily
activity  and  hospital  discharge.
This  study  aims  to  analyze  the  experience  of  a  vascu-
lar  single  centre  with  competence  in  performing  EVAR  by
both  percutaneous  (pEVAR)  and  surgical  (cEVAR)  access.
These  procedures  were  performed  by  the  same  set  of
surgeons,  with  selected  patients  compatible  to  both
a
(
aechniques,  with  the  objective  to  produce  data  and  evidence
n  an  uncontrolled  environment,  being  the  closest  possible
o  the  clinical  practice.
ethods
etrospective,  single-centre,  non-randomized  study,  con-
ucted  in  the  period  between  January  2013  and  January
015,  in  order  to  compare  the  results  of  endovascular
reatment  of  abdominal  aortic  aneurysms  by  percutaneous
emoral  access  (pEVAR  --  group  1)  with  the  results  the  sur-
ical  femoral  access  (cEVAR  --  Group  2).  The  percutaneous
ccess  included  in  all  patients  a pre-assembly  of  bilateral
emoral  closure  devices  (Proglide® --  Abbott®).
The  inclusion  criteria  were:  (a)  pEVAR  in  an  infrarenal
ortic  aneurysm  with  a  bifurcated  stent  graft  (group  1);
b)  cEVAR  in  an  infrarenal  aortic  aneurysm  with  a  bifurcated
tent  graft  (group  2);  (c)  elective  procedures;  (d)  asymp-
omatic  patients;  (e)  fusiform  or  saccular  aneurysms,  with
avourable  anatomy.
The  exclusion  criteria  were:  (a)  thoracic,  thoracoabdom-
nal,  pararenal  or  juxtarenal  aneurysm;  (b)  symptomaticnatomy;  (d)  complex  endovascular  or  hybrid  procedure;
e)  femoral  circumference  calciﬁcation  >50%  identiﬁed  by
rterial  Doppler  ultrasound;  (f)  extensive  inguinal  scar,
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revious  femoral  complication  or  intervention;  (g)  coagu-
ation  disorders.
There  was  no  preference  of  bifurcated  aortic  endografts.
hree  types  of  endorafts  were  used:  Zenith®,  Excluder® and
ndurant®.
Were  deﬁned  as  primary  endpoints:  (a)  complication  in
he  femoral  access;  (b)  surgical  time.  In  access  complica-
ion,  four  main  points  were  analyzed:  (a)  major  bleeding,
eﬁned  as  identiﬁed  hematic  loss  requiring  blood  transfu-
ion;  (b)  minor  bleeding  as  a  bruise  or  haematoma  without
he  need  for  transfusion  support;  (c)  lymphatic  drainage
t  the  site  of  percutaneous  or  surgical  femoral  access;
d)  inguinal  pain;  (e)  lower  limb  oedema,  unilateral  or
ilateral.
As  secondary  endpoints  were  selected:  (a)  type  of  anaes-
hesia;  (b)  length  of  hospital  stay;  (c)  hematic  loss;  (b)  renal
unction.  Hematic  loss  is  deﬁned  as  haemoglobin  value  dif-
erential  collected  by  peripheral  venous  puncture  before
nd  after  surgery.  Renal  function  was  assessed  by  analytical
alue  of  serum  creatinine  before  and  after  surgery  (mini-
um  interval  of  24  h).
The  access  choice  was  based  on  personal  experi-
nce  of  a  surgeon  capable  of  independent  use  of  the
wo  techniques,  after  guaranteed  the  exclusion  criteria.
ll  percutaneous  accesses  were  ultrasound  guided  and
t  least  one  loading  dose  of  5000  units  of  unfraction-
ted  heparin  was  administrated  at  the  beginning  of  the
rocedure.
tatistical  analysistatistical  analysis  was  performed  using  the  SPSS  23.0  pro-
ramme  with  descriptive  evaluation  of  demographic  data,
nd  applying  the  2 tests  for  the  analysis  of  categorical
ariables  and  the  t  test  for  continuous  variables.
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Table  1  Demographic  factors,  aneurymal  characteristics  and  com
Total  
Age  Years
Mean  75  
Minimum 56  
Maximum 88  
Gender %
Masculin  85  
Feminin 15  
AAA diameter Milimeters
Mean  58  
Comorbidities  %
1. Arterial  hypertension  73.1  
2. Dyslipidemia  57.7  
3. CID  38.8  
4. COPD  38.8  
5. CRF  23.1  
6. Diabetes  19.2  
AAA, abdominal aortic aneurysm; CID, coronary ischaemic disease; C
failure.M.M.  Vieira  et  al.
esults
 total  of  6  patients  submitted  to  pEVAR  (group  1)  were  iden-
iﬁed  in  the  described  period.  Of  the  patients  submitted  to
EVAR  (group  2)  in  this  same  interval,  a  random  selection  of
0  patients  was  selected  and  deﬁned  as  the  control  group.
The  average  age  of  both  groups  was  75  ±  8  years  (min:  56;
ax:  88  years)  with  a  mean  age  of  72  years  for  group  1  and
6  years  for  group  2.  Twenty-two  patients  (85%)  were  male.
he  average  diameter  of  the  aneurysm  was  58  mm  (Table  1).
The  most  common  co-morbidities  were  arterial  hyperten-
ion  (73%),  dyslipidemia  (58%),  coronary  ischaemic  disease
39%),  chronic  obstructive  pulmonary  disease  (39%),  chronic
enal  failure  (23%)  and  type  2  diabetes  (19%).
Comparing  the  two  groups,  there  were  no  signiﬁcant  dif-
erences  between  each  comorbidities  (p  >  0.05),  registering
owever  more  prevalence  in  group  2  of  coronary  ischaemic
isease  (45%),  chronic  obstructive  pulmonary  disease  (45%)
nd  chronic  renal  failure  (43%)  (Table  1).
rimary  endpoints
he  overall  major  bleeding  rate  was  11.5%,  not  obtain-
ng  however  statistical  signiﬁcance  between  the  two  groups
p  =  0.438),  unlike  minor  bleeding,  higher  in-group  1  (11.5%,
 = 0.008).  Lymphatic  drainage,  inguinal  pain  and  lower
imb  oedema,  all  with  an  overall  incidence  rate  of  3.8%,
lthough  higher  in  group  1,  achieved  no  signiﬁcant  differ-
nce  between  groups  (p  =  0.769)  (Table  2).
The  mean  operative  time  was  194.5  ±  34  min.  The  mean
n-group  1  was  163.2  ±  19.6  min  (min:  125;  max:  180)  and
roup  2  reached  203.9  ±  31.8  min  (min:  144;  max:  280).
he  analysis  does  not  showed  differences  between  groups
p  =  0.206).  Observing  the  higher  range  of  surgical  time
n  group  2  (144  to  280  min)  evidenced  in  the  analysis  of
orbidities.
pEVAR  cEVAR  p
72  76  0.54
56  64
78  88
67  90
0.2233  10
55  63  0.47
83  70  0.47
83  55  0.49
17  45  0.23
17  45  0.23
0  43  0.17
0  25  0.23
OPD, chronic obstructive pulmonary diseade; CRF, chronic renal
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Table  2  Results  of  primary  and  secondary  endpoints.
Total  pEVAR  cEVAR  p
Access  complication %
Major  bleeding  11.5  0  15  0.438
Minor bleeding  11.5  5  0  0.008
Linfatic drainage  3.8  0  5  0.769
Inguinal pain  3.8  0  5  0.769
Oedema 3.8  0  5  0.769
Surgical time  Minutes
Mean  ±  SD  194.5  ±  33.9  163.2  ±  19.6  203.9  ±  31.8  0.206
Median 193  169  209
Minimum 125  125  144
Maximum 280  180  280
ANOVA table  0.007
Anaesthesia N  (total  =  26)
Epidural  23  3  20  0.003
Local 3  3  0
Hospital stay Days
Mean  5.2  3.17  6.15  0.022
Hematic Loss  g/dl
Mean  2.45  ±  1.09  1.40  ±  0.76  2.77  ±  1.36  0.171
Renal function  variation mg/dl
Mean  0.17  ±  0.1 0.15  ±  0.7 0.18  ±  0.11 0.134
SD, standard deviation.
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aFigure  1  Cluster  bar  graph  demonstrates  higher  hospital  stay
in surgical  femoral  access  compared  to  percutaneous.
clustered  bar  chart  (Fig.  1),  we  proceeded  to  the  analysis
of  intra-group  variance  with  ANOVA  table  which  revealed
signiﬁcant  difference  of  the  surgical  times  between  the  two
groups  (p  =  0.007),  being  higher  in  group  2  (Table  2).Secondary  endpoints
The  most  common  type  of  anaesthesia  was  the  epidural
(n  =  20)  with  statistical  signiﬁcance  in  relation  to  the  local
a
a
gnaesthesia  (p  = 0.003).  This  was  the  technique  of  choice
n  every  patient  of  group  2  and  three  patients  in  group  1,
he  remainder  being  subject  to  local  anaesthesia.  None
f  the  patients  underwent  the  procedure  under  general
naesthesia  (Table  2).
The  average  length  of  hospital  stay  was  5.2  ±  1.9  days
ith  3.17  days  in  group  1  and  6.15  days  in  group  2,  reaching
igniﬁcant  difference  between  the  two  groups  (p  =  0.022).
The  haemoglobin  differential  before  and  after  surgery
as  not  signiﬁcant  between  the  two  groups  (p  =  0.171),  with
ematic  loss  of  1.4  ±  0.8  g/dl  in  group  1  and  2.8  ±  1.4  g/dl
n  group  2  (Fig.  2).
Renal  function  was  not  signiﬁcantly  different  between
he  two  groups  (p  = 0.134),  with  0.15  ±  0.07  mg/dl  differ-
nce  in  plasma  creatinine  in  group  1  and  0.1  ±  0.18  mg/dl
n  group  2  (Fig.  3).
iscussion
lthough  recent  studies  such  as  EVAR  trial1 or  the  Cochrane
eview  by  Paravastu  et  al.  in  20142 not  demonstrate  beneﬁt
n  the  medium  and  long-term  results  of  endovascular  treat-
ent  of  aortic  aneurysms  compared  to  surgical  approach,
echnological  and  scientiﬁc  expansion  with  application  in
uptured,  young  patients  or  complicated  and  complex
neurysms  provided  an  enlargment  and  afﬁrmation  of  EVAR
s  ﬁrst-line  therapy  for  infra-renal  aortic  aneurysms.
It  has  also  been  observed  in  recent  years  a  progressive
nd  supportive  minimal  invasive  approach  to  medical  and
lobal  surgical  intervention.  In  this  appreciation,  for  nearly
256  
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Figure  2  Cluster  bar  graph  shows  higher  haematic  loss  in
surgical femoral  access.
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Figure  3  Cluster  bar  graph  shows  no  difference  in  creatinine
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with  pEVAR,  representing  50%  of  the  patients  in  this  study,
steadily  increasing  in  time.  This  factor  is  also  associated  withariation  related  to  femoral  access.
0  years  that  percutaneous  access  for  EVAR  has  gained  more
upporters  with  some  centres  currently  holding  more  than
0%  of  procedures  using  this  technique  with  success  rates
lose  to  100%.4--9
The  scientiﬁc  evidence  demonstrated  by  the  PEVAR  trial4
n  2014  or  more  recently  by  Buck  et  al. 5 with  analysis  of  over
000  patients  undergoing  pEVAR,  show  excellent  results  of
his  technique  in  relation  to  surgical  femoral  approach  with
igh  success  rate,  shorter  operative  time  and  hospitaliza-
ion,  and  lower  complication  rate.
This  study  aims  to  analyze  the  results  of  pEVAR  in
 vascular  department  that  performs  both  techniques  by
he  same  set  of  professionals.  The  analysis  is  compared
ith  the  results  of  the  group  submitted  cEVAR,  and  the  deci-
ion  on  the  type  of  access  per  patient  was  made  based  on
reference  and  experience  of  the  professional,  obtaining
n  review  independent  of  randomization,  being  the  closest
ossible  to  daily  clinical  practice.
a
rM.M.  Vieira  et  al.
All  the  patients  analyzed  had  clinical  and  anatomi-
al  characteristics  compatible  with  both  techniques.  There
ere  no  signiﬁcant  differences  in  all  comorbidities  in  both
roups;  however,  the  surgical  approach  group  had  higher
revalence  of  coronary  ischaemic  disease  group  and  chronic
idney  failure  as  well  as  lung  disease.
In  primary  endpoints  analysis,  the  most  frequent  access
omplication  rate  was  bleeding,  reaching  11.5%,  not  signiﬁ-
antly  different  between  the  two  groups  (bleeding  requiring
ransfusion  support).  Nevertheless,  minor  bleeding  without
eed  for  intervention  reaches  statistical  signiﬁcance,  higher
n  pEVAR.  This  is  probably  related  to  the  initial  service  expe-
ience  in  the  use  of  percutaneous  closure  devices.  This  fact
as  recently  been  demonstrated  by  Bechara  et  al.  where  the
losing  failure  rate  decreased  from  45%  to  5%  with  increasing
perator  experience,  being  this  one  of  the  main  factors  asso-
iated  with  the  treatment  success.10--12 This  success  rate  also
elates  with  use  of  ultrasound  to  percutaneous  puncture,13
 technique  that  since  2007  is  positively  related  to  the
eduction  of  local  complications.  Another  interesting  fact
s  that  the  use  of  therapeutic  intraoperative  levels  of  hep-
rin  was  not  associated  with  increased  bleeding  rate,  even  if
ot  performing  reversal  at  the  end  of  the  intervention.14,15
The  remaining  access  complications  such  as  lymphatic
rainage,  inguinal  pain  at  the  site  of  access  or  leg
edema  did  not  obtain  signiﬁcant  differences  between  the
roups,  despite  being  expecting  an  increase  in  cEVAR,  with
verall  rate  of  3.8%,  in  line  with  current  evidence,  that
anges  from  2.9%  to  10.1%.16,17
In  this  study  we  considered  three  types  of  bifurcated
ndograft  most  used  in  our  country,  with  sheath  diame-
er  ranging  between  14F  and  18F.  Despite  the  described
ncreased  rate  of  access  complications  using  sheath  diam-
ters  higher  than  20F,  obesity  and  femoral  calciﬁcation,11,18
here  is  no  scientiﬁc  evidence  to  support  deleting  the  percu-
aneous  access  from  these  patients.  As  described  by  several
uthors,19--22 percutaneous  access  can  be  safely  performed  in
bese  patients  with  calciﬁed  femoral  arteries  using  sheaths
p  to  24F.  These  results  apparently  persist  in  the  long-term
ollow-up,  with  late  complication  rate  around  2%  at  twelve
onths.23
Analysing  the  surgical  time  for  intervention,  with  an
verage  of  195  min  globally,  there  was  no  expected  signiﬁ-
ant  differences  between  the  two  groups.  However,  besides
he  difference  between  the  two  means  (pEVAR  vs.  cEVAR:
63  vs.  204  min),  a  wide  range  of  values  in-group  2  raised
he  possibility  of  having  high  intra-group  variance  of  values
hat  would  associate  the  lack  of  signiﬁcance.  The  bar  clus-
er  graph  showed  higher  surgical  time  tendency  in  group  2.
he  analysis  of  the  ANOVA  table  proves  the  hypothesis,
ince  the  intra-group  variance  was  statistically  signiﬁcant
p  <  0.05).  It  is  thus  understood  that  the  tendency  for  sus-
ained  reduction  of  surgical  time  with  the  pEVAR  was  not
tatistically  supported  by  the  lower  sample  homogeneity  of
he  cEVAR  group.
The  analysis  of  the  secondary  endpoints  shows  that
lthough  most  patients  have  been  undergoing  epidural
naesthesia  (77%),  there  is  a  tendency  for  local  anaesthesia decreased  surgical  time,24 as  well  as  the  postoperative
ecovery  and  hospital  discharge.
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The  length  of  hospital  stay  was  signiﬁcantly  lower  in
patients  in-group  1,  with  a  mean  difference  of  around  3  days.
This  factor  is  apparently  related  to  the  type  of  anaesthesia
and  decrease  in  access  complications.  Despite  there  was  no
signiﬁcant  difference  in  the  later,  those  complications  were
5%  lower  in  the  percutaneous  access.
Despite  having  not  been  a  subject  of  this  study,  this
data  creates  an  assumption  that  percutaneous  access  may
decrease  total  costs,  not  balanced  by  the  cost  of  percuta-
neous  closure  devices.  This  hypothesis  was  demonstrated
by  Jean-Baptiste  et  al.25 in  2008  where  the  difference  in
length  of  hospital  stay  was  related  to  the  decrease  in  total
costs  in  patients  undergoing  pEVAR.  This  cost  can  be  even
lower  if  one  considers  the  ambulatory  hypothesis  of  percu-
taneous  procedure  in  patients  with  good  functional  capacity
and  low  medical  risk,  without  complication  during  the
procedure.26
Analysing  the  hematic  loss  and  change  in  renal  function
between  the  two  groups,  there  was  no  signiﬁcant  differ-
ences.  However,  the  difference  in  hematic  loss  between
groups  reaches  1.3  g/dl,  with  a  greater  loss  tendency  for
patients  undergoing  surgical  access,  fact  evidenced  by  the
analysis  of  the  clustered  bar  graph.  That  difference  was
not  observed  in  renal  function  variation,  with  close  serum
creatinine  values  before  and  after  procedure.
This  study  presents  some  limitations  as  the  small  num-
ber  of  selected  patients,  which  is  related  to  the  recent
initiation  of  the  percutaneous  technic  in  EVAR,  despite  the
pre-existing  experience  in  other  percutaneous  arterial  treat-
ments  (occlusive  disease  for  example),  a  number  that  will
signiﬁcantly  increase  in  the  forthcoming  months.
Another  limitation  is  related  to  the  non-randomization
of  patient.  There  is  thus  a  natural  selection  bias,  which  may
alter  the  results.  However,  not  excluding  the  logical  statisti-
cal  limitations,  the  option  allowed  to  have  a  close  approach
of  the  results  of  the  reality  of  clinical  practice.
Conclusion
Despite  the  limited  experience,  the  pEVAR  presents  itself
as  a  safe  and  effective  option  compared  to  cEVAR,
with  lower  local  complications  rate,  decreased  surgical
time  and  hospitalization.  It  is  still  required  a  sam-
ple  increase  and  medium  and  long  term  outcomes  to
conﬁrm  the  percutaneous  access  as  ﬁrst-line  option  in
patients  undergoing  endovascular  repair  of  abdominal  aortic
aneurysms.
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